München (ots) - Neue Geschichten mit und über Deutschlands wahrscheinlich bekannteste Glamour-Familie ...
Accuray and N.N. Burdenko National Scientific and Practical Center for Neurosurgery Sign Collaboration Agreement to Expand Radiosurgery Education and Training
Sunnyvale, California (ots/PRNewswire) - Partnership Creates Strategic Alliance for Clinical Education and Training in Robotic Radiosurgery
Accuray Incorporated (NASDAQ: ARAY) announced today the signing of a three-year Collaboration and Support Agreement with the N.N. Burdenko National Scientific and Practical Center for Neurosurgery in Moscow, Russia. The collaboration is designed to expand education and training opportunities for medical physicists using the CyberKnife® System to treat conditions within the brain and spine. The institute is one of the world's largest neurosurgical clinics and has a long and successful history of treating intracranial and spinal indications.
The agreement, which establishes a collaborative relationship between Accuray and the Institute, will enable physicists from Russia to receive peer-to-peer training from the Burdenko team on the most current CyberKnife System treatment planning and quality control techniques, and treatment protocols for intracranial, spine, and other extracranial cases. Attendees will also have the opportunity to observe patient treatments.
"We are very pleased to collaborate with the renowned Burdenko Center on the training of both experienced and new medical physicists. We believe the CyberKnife System offers distinct advantages in the treatment of neurological conditions and are committed to working with the local Burdenko team to ensure our customers will benefit from the System's unique functionalities," said Matthias Franz, EIMEA General Manager and VP Commercial Operations at Accuray.
Established 84 years ago, the N.N. Burdenko National Scientific and Practical Center for Neurosurgery has built strong clinical and scientific traditions, enabling its medical team to develop expertise in the diagnosis and treatment of neurological conditions. Since its founding, the institute has been a reference center for the treatment of patients with diseases of the central and peripheral nervous system, not only in Russia, but in all former states of the Soviet Republic.
The Department of Stereotactic Radiotherapy and Radiosurgery of the N.N. Burdenko National Scientific and Practical Center for Neurosurgery is equipped with modern radiosurgical and radiation oncology technology including the CyberKnife System, which was the first of its kind in Russia when installed in 2009. Recently upgraded, the CyberKnife System provides better image guidance and tracking capabilities as well as a more efficient workflow, enabling the center to treat more patients per day. The technology has been used to treat more than 4,500 patients, with an average of 15 patients per day.
"We chose the CyberKnife System because it enables us to deliver both radiosurgery and hypofractionated treatments, providing significant benefits for patients with a variety of indications including spinal and intracranial lesions and in some cases, metastatic lung, liver, and bone cancer," said Professor Andrey Golanov, Head of the Stereotactic Radiotherapy and Radiosurgery Department, N.N. Burdenko National Scientific and Practical Center for Neurosurgery. "We are launching the training program to help other physicians and physicists optimize their use of the System. The Accuray - Burdenko agreement will enable us to provide our colleagues from other centers with training which will help them gain an understanding of what is required to support a successful CyberKnife System program at their center."
The CyberKnife System delivers radiosurgery and stereotactic body radiation therapy (SBRT), enabling precise, high quality dose distributions to be confidently delivered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life. It is the only System capable of tracking and automatically correcting for target motion in real time, even while the tumor moves. The System offers a non-invasive treatment option for precisely treating lesions of different sizes and locations, including tumors located near critical structures.
Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company that develops, manufactures, and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit http://www.accuray.com .
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, market acceptance of our new technologies, patient outcomes and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 24, 2016, the company's reports on Form 10-Q, filed on November 1, 2016 and February 3, 2017, and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.